Core Insights - Avoro Capital Advisors LLC acquired a new stake in Tango Therapeutics, purchasing 545,000 shares valued at approximately $4.58 million, representing about 0.40% ownership of the company [2] - Several institutional investors have increased their stakes in Tango Therapeutics, with Dynamic Technology Lab Private Ltd increasing its stake by 139.7% and Ameritas Investment Partners Inc. raising its stake by 78.8% [3] - Tango Therapeutics has a market capitalization of $2.47 billion, with a 1-year price range of $1.03 to $17.63 and a current trading price of $17.30 [4] Financial Performance - Tango Therapeutics reported an EPS of -$0.29, exceeding the consensus estimate of -$0.31 by $0.02, with a negative net margin of 151.15% and a negative return on equity of 50.30% [5] - Analysts forecast an EPS of -$1.19 for the current fiscal year [5] Analyst Ratings - HC Wainwright raised its price target for Tango Therapeutics from $13.00 to $27.00, while Stifel Nicolaus increased its target from $15.00 to $24.00, both giving a "buy" rating [6] - The average rating for Tango Therapeutics is "Moderate Buy" with a consensus target price of $19.50 [6] Insider Transactions - CFO Daniella Beckman sold 10,317 shares at an average price of $12.26, resulting in a 5.30% decrease in her position [7] - Director Barbara Weber sold 30,519 shares at the same average price, representing a 1.84% decrease in her holdings [7] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines that target genetic vulnerabilities in cancer cells [8] - The company's lead pipeline includes early-stage programs aimed at selectively disabling DNA repair proteins in tumor cells [9]

Core Insights - IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE892, a potential best-in-class PRMT5 inhibitor targeting MTAP-deleted solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic cancer [1] - The company plans to deprioritize combination activities with Trodelvy to focus on its proprietary MTAP-deleted and CDKN2A pipeline, aiming for a first-in-class CDKN2A development candidate nomination in H2 2026 and an IND submission in H1 2027 [1] Group 1: IDE892 Development - The first patient has been enrolled in the Phase 1 trial evaluating IDE892, which will assess safety, tolerability, pharmacokinetics, and pharmacodynamics as a monotherapy and in combination with IDE397 [1] - IDE892 exhibits approximately 1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes and demonstrates single-digit nanomolar potency in MTAP-deleted cell lines [1] - Preclinical studies show that dual inhibition of PRMT5 and MAT2A with IDE892 and IDE397 resulted in durable tumor regressions in MTAP-deleted tumor models [1] Group 2: CDKN2A Program - IDEAYA is advancing its CDKN2A-deficiency program, targeting a first-in-class development candidate selection in H2 2026 and an IND submission in H1 2027 [1] - CDKN2A deficiency is prevalent in over 80% of pancreatic cancer cases and is often co-deleted with MTAP, creating opportunities for rational combination therapies [1] - The company has demonstrated robust monotherapy efficacy with its CDKN2A lead in multiple preclinical models, including a KRAS mutation pancreatic model [1] Group 3: Strategic Prioritization - As part of its strategic focus, IDEAYA has deprioritized clinical combination activities with Trodelvy and will conclude enrollment in ongoing Phase 1/2 trials with Gilead [1] - The company may explore additional combinations between IDE397 and other TOP1 payload ADCs, including IDE034, in the context of MTAP-deleted cancers [1] - MTAP deletion occurs in 15-20% of NSCLC, up to 40% of pancreatic cancer, and approximately 15% of all solid tumors, highlighting the unmet need for targeted therapies [1]

Core Points - Tango Therapeutics, Inc. announced the grant of stock options and restricted stock units (RSUs) to a new employee as part of its 2023 Inducement Plan [1][2] - The stock options granted total 367,500 shares with an exercise price of $11.94 per share, equal to the closing price on the grant date [3] - The RSUs granted total 60,000 shares, with a vesting schedule over three years [3] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [4] - The company utilizes the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related pathways [4]

Core Insights - Tango Therapeutics is focused on advancing its lead clinical program, vopimetostat, which shows best-in-class potential for treating MTAP-deleted pancreatic cancer and is set to launch a pivotal study in 2026 [2][6] - The company has entered a clinical supply agreement with Erasca to explore vopimetostat in combination with ERAS-0015, enhancing its position in the oncology market [2][6] - As of December 31, 2025, Tango Therapeutics reported a strong cash position of $343 million, providing a financial runway into 2028 [8][13] Clinical Pipeline Updates - Vopimetostat is a selective once-daily PRMT5 inhibitor, with ongoing robust enrollment in combination studies with Revolution Medicines' RAS(ON) inhibitors for pancreatic and lung cancer [3][6] - Initial Phase 1/2 data for the combination studies are expected in 2026, which may inform future pivotal trials [6] - The company is also advancing its TNG456 monotherapy, with initial safety and efficacy data anticipated in 2026 [6] Financial Performance - Collaboration revenue for the fourth quarter of 2025 was $0, down from $5.4 million in the same period in 2024, while total revenue for the year was $62.4 million, up from $30 million in 2024 [9][10] - Research and development expenses for Q4 2025 were $32.1 million, slightly up from $31.3 million in Q4 2024, while total R&D expenses for the year decreased to $132.2 million from $143.9 million [11] - The net loss for Q4 2025 was $38.7 million, or $0.29 per share, compared to a net loss of $30.8 million, or $0.32 per share, in Q4 2024 [13][20] Corporate Updates - The company appointed Philippe Serrano as Chief Regulatory Officer to enhance its regulatory leadership [5][7] - In January 2026, Dr. Malte Peters succeeded Dr. Barbara Weber as CEO, with Weber transitioning to Executive Chair [16] - The Board of Directors was expanded with the appointment of Mr. Sung Lee, bringing over 20 years of finance leadership experience [16]

Core Insights - Boxer Capital Management, LLC disclosed a purchase of 1,104,734 shares of Tango Therapeutics, with an estimated transaction value of $9.52 million based on average quarterly pricing [1][2] - The acquisition increased Boxer Capital's stake in Tango Therapeutics to 21.09% of its 13F reportable AUM as of December 31, 2025 [3] - Tango Therapeutics shares were priced at $12.80 as of February 17, 2026, reflecting a 426.7% increase over the past year, significantly outperforming the S&P 500 by 406.30 percentage points [3] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on developing targeted cancer therapies using synthetic lethality [5][6] - The company has a strategic collaboration with Gilead Sciences for the development and commercialization of cancer therapies [6] - Tango Therapeutics targets genetically defined cancers and emphasizes precision medicine in its approach [7] Financial Metrics - As of February 17, 2026, Tango Therapeutics had a market capitalization of $1.41 billion, with a revenue of $66.50 million and a net income of -$100.52 million (TTM) [3]

Financial Results Announcement - Tango Therapeutics, Inc. will report its fourth quarter 2025 financial results on March 5, 2026, before the U.S. financial markets open [1] - The company does not plan to hold a conference call following the financial results announcement [1] Upcoming Investor Conferences - Tango Therapeutics management is scheduled to participate in three investor conferences: TD Cowen 46 Annual Health Care Conference in Boston, Barclays 28 Annual Global Healthcare Conference in Miami, and hosting 1x1 meetings on March 10 [1] - A corporate presentation is set for March 4 from 1:10 to 1:40 PM ET [4] - A fireside chat is scheduled for March 11 from 3:00 to 3:30 PM ET [5] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [3] - The company utilizes the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related targets [3]

Core Insights - Artios Pharma Limited has appointed three senior leaders to enhance its late-stage development capabilities and prepare for commercial readiness, including Roy W. Ware as Chief Manufacturing and Technology Officer, Caryn Barnett as Vice President of Clinical Operations, and Pablo Lee as Vice President of Medical Affairs [1][6] Group 1: Leadership Appointments - Roy W. Ware, PhD, MBA, brings over 20 years of experience in CMC strategy, manufacturing, and global supply chain leadership, previously serving at Chimerix where he oversaw FDA submissions for Tembexa® and Modeyso® [3] - Caryn Barnett has over 30 years of experience in biopharmaceuticals, having led late-phase oncology programs through registration and approval, including Cyramza® and Verzenio® [4] - Pablo Lee, MD, MBA, has more than 25 years of experience in medical practice and global medical affairs, previously involved in the launch planning of Modeyso® and has held senior roles at Eli Lilly [5] Group 2: Company Focus and Pipeline - Artios Pharma is focused on developing new classes of medicines that target DNA Damage Response (DDR) pathways, with a mission to deliver meaningful survival benefits for cancer patients [7] - The company is advancing its lead program, alnodesertib, into late-stage development and potential commercialization in the U.S., while also executing a Phase 2 study for ART6043 [1][2]

Core Insights - Tango Therapeutics, Inc. is participating in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 PM EST, with CEO Malte Peters scheduled for a fireside chat [1] - The event will be accessible via a live webcast on the company's website, with a replay available for 90 days post-presentation [2] - Tango Therapeutics is focused on discovering novel drug targets and developing precision medicine for cancer treatment, utilizing the genetic principle of synthetic lethality [3]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Suzhou Genhouse Bio Co., Ltd. 勤浩醫藥（蘇州）股份有限公司 (A joint stock company incorporated in the People's Republic of China ...

Core Viewpoint - Tango Therapeutics, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its focus on precision medicine for cancer treatment [1]. Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision medicine for cancer treatment [3]. - The company employs the genetic principle of synthetic lethality to identify and create therapies targeting critical cancer-related elements [3]. Event Details - Barbara Weber, M.D., the President and CEO of Tango Therapeutics, will deliver the corporate presentation at 9:45am PST/12:45pm EST [1]. - A live webcast of the presentation will be available on the company's website, with a replay archived for 90 days post-event [2].